Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Combined With Toripalimab in High-Risk NMIBC
NCT07783815Phase 1Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disitamab vedotin and toripalimab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Recurrence-Free Survival at 1 year. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07783815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783815.